Pacific Edge Limited (PFGTF) has released an update.
Pacific Edge Limited’s Annual Report for the fiscal year ending March 31, 2024, highlights their commitment to transparency and stakeholder engagement, with a comprehensive overview of operational and financial performance. The report, audited by PwC, complies with legal and governance standards and includes crucial information on the company’s advancements in bladder cancer diagnostics. Investors can access the report electronically on Pacific Edge’s website, emphasizing their ongoing global impact in cancer diagnostics through their Cxbladder tests.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
